title: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
abstract: Four oestrogen-regulated proteins of reported prognostic value, oestrogen receptor (ER), progesterone receptor (PR), pS2 and cathepsin D (Cat D), have been quantified by immunoassays, and the latter studied by immunohistochemistry (IHC) in primary tumours from clinically node-negative early breast cancer patients, entered into a trial of breast conservation therapy in which all the patients received adjuvant tamoxifen. ER, PR and pS2 significantly co-correlated but none correlated with Cat D. ER, PR and pS2, but not Cat D, were significantly associated with tumour size and grade, although Cat D tended to show an inverse relationship with the latter. Cat D (radioimmunoassay) in pmol/mg significantly correlated with the IHC score for Cat D in carcinoma cells as well as the number of Cat D-expressing macrophages. At a median follow-up of only 16 months, recurrence was significantly more common in patients with tumours having negative status for ER, PR and pS2 but was not associated with Cat D status.
authors.affiliation: University Department of Surgery, Queen Elizabeth Hospital, Birmingham, U.K.
authors.forename: P S
authors.initials: PS
authors.lastname: Stonelake
authors.forename: P G
authors.initials: PG
authors.lastname: Baker
authors.forename: W M
authors.initials: WM
authors.lastname: Gillespie
authors.forename: J A
authors.initials: JA
authors.lastname: Dunn
authors.forename: D
authors.initials: D
authors.lastname: Spooner
authors.forename: J M
authors.initials: JM
authors.lastname: Morrison
authors.forename: N J
authors.initials: NJ
authors.lastname: Bundred
authors.forename: G D
authors.initials: GD
authors.lastname: Oates
authors.forename: M J
authors.initials: MJ
authors.lastname: Lee
authors.forename: J P
authors.initials: JP
authors.lastname: Neoptolemos
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D002402:Cathepsin D / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D011506:Proteins; D011863:Radioimmunoassay; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D011506:Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins; D013629:Tamoxifen; D002402:Cathepsin D